Post by
Noteable on Jul 30, 2023 1:24pm
Roche anti-TIGIT hope turns to Tecentriq
Roche's anti-TIGIT drug tiragolumab also has not done very well - placing Roche's continued hope on their immune checkpoint inhibitor Tecentriq.
https://www.reuters.com/business/healthcare-pharmaceuticals/roches-late-stage-trial-two-lung-cancer-drugs-fails-2022-05-11/
Comment by
Buckhenry on Jul 30, 2023 4:29pm
Yes I would like to thank all the dreamers for their constant barage of worthless posts about all the other companies that have been bought for jillions of dollars.... and how does this relate to oncy... is their a direct correlation here. Or is it all hot air and wishful thinking... well... perhaps or maybe I suppose.
Comment by
Noteable on Jul 30, 2023 5:13pm
All this is effectively related to ONCY given pelareorep's ability to convert an otherwise immunosuppressive tumor microenvironment (TME) into one that is favorable to combination immunotherapy, and do so synergistically.
Comment by
Noteable on Jul 30, 2023 5:23pm
So ... for those who got lost on the way here, this again bring up the subject of triplet therapy involving ONCY's pelareorep. Therfore, how we got here is not in the same way to where we are going.